Radiation therapy earns its place in liver cancer treatment. A systematic review of nearly 5,000 patients found that external beam radiation therapy (EBRT) produces survival outcomes comparable to traditional treatments like ablation, resection, and transplant for early-stage hepatocellular carcinoma (HCC). The findings were strong enough to prompt updated BCLC guidelines to officially recommend EBRT as a first-line option for this patient population.
Radiation therapy earns its place in liver cancer treatment
For years, external beam radiation therapy (EBRT) was the overlooked option in early-stage hepatocellular carcinoma (HCC) — largely left out of major guidelines due to limited overall survival data. That's changing. A systematic review of nearly 5,000 patients across 11 countries found that EBRT produces survival outcomes on par with traditional first-line therapies like ablation, resection, and liver transplant, prompting updated Barcelona Clinic Liver Cancer (BCLC) guidelines to officially add it as a recommended treatment option.
The appeal of EBRT is real: it's completely noninvasive, patients walk in and out on the same day, and it can reach tumors that needles can't. It's also better tolerated than some intra-arterial therapies. The main drawbacks? It typically requires three to five treatment sessions (vs. one for ablation or TACE), and it must be used carefully in patients with compromised liver function.
By the Numbers
Why it matters: With EBRT now endorsed in updated BCLC guidelines, clinicians have a validated, noninvasive first-line option for early-stage HCC — especially valuable for patients who can't tolerate sedation or where lesion location makes ablation impractical. Prospective trials comparing modalities are still needed to guide patient selection.
